These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. Childs R; Chernoff A; Contentin N; Bahceci E; Schrump D; Leitman S; Read EJ; Tisdale J; Dunbar C; Linehan WM; Young NS; Barrett AJ N Engl J Med; 2000 Sep; 343(11):750-8. PubMed ID: 10984562 [TBL] [Abstract][Full Text] [Related]
3. Allogeneic blood stem cell transplantation after a reduced-intensity, preparative regimen: a pilot study in patients with refractory malignancies. Pedrazzoli P; Da Prada GA; Giorgiani G; Schiavo R; Zambelli A; Giraldi E; Landonio G; Locatelli F; Siena S; Della Cuna GR Cancer; 2002 May; 94(9):2409-15. PubMed ID: 12015766 [TBL] [Abstract][Full Text] [Related]
4. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. Petersen SL Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527 [TBL] [Abstract][Full Text] [Related]
5. Posttransplant administration of cyclophosphamide and donor lymphocyte infusion induces potent antitumor immunity to solid tumor. Eto M; Kamiryo Y; Takeuchi A; Harano M; Tatsugami K; Harada M; Kiyoshima K; Hamaguchi M; Teshima T; Tsuneyoshi M; Yoshikai Y; Naito S Clin Cancer Res; 2008 May; 14(9):2833-40. PubMed ID: 18451251 [TBL] [Abstract][Full Text] [Related]
6. Nonmyeloablative stem cell transplantation in metastatic renal cell carcinoma: delayed graft-versus-tumor effect is associated with chimerism conversion but transplantation has high toxicity. Massenkeil G; Roigas J; Nagy M; Wille A; Stroszczynski C; Mapara MY; Loening S; Dörken B; Arnold R Bone Marrow Transplant; 2004 Aug; 34(4):309-16. PubMed ID: 15220955 [TBL] [Abstract][Full Text] [Related]
15. Reduced intensity conditioning regimen followed by glycosylated G-CSF mobilized PBSCT in patients with solid tumors and malignant lymphomas. Castagna L; Bertuzzi A; Nozza A; Siracusano L; Balzarotti M; Magagnoli M; Sarina B; Timofeeva I; Sinnone M; Grimoldi MG; Farè M; Santoro A Bone Marrow Transplant; 2002 Aug; 30(4):207-14. PubMed ID: 12203136 [TBL] [Abstract][Full Text] [Related]
16. Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors. Ueno NT; Cheng YC; Rondón G; Tannir NM; Gajewski JL; Couriel DR; Hosing C; de Lima MJ; Anderlini P; Khouri IF; Booser DJ; Hortobagyi GN; Pagliaro LC; Jonasch E; Giralt SA; Champlin RE Blood; 2003 Nov; 102(10):3829-36. PubMed ID: 12881308 [TBL] [Abstract][Full Text] [Related]
17. Successful treatment of metastatic renal cell carcinoma with a nonmyeloablative allogeneic peripheral-blood progenitor-cell transplant: evidence for a graft-versus-tumor effect. Childs RW; Clave E; Tisdale J; Plante M; Hensel N; Barrett J J Clin Oncol; 1999 Jul; 17(7):2044-9. PubMed ID: 10561256 [TBL] [Abstract][Full Text] [Related]
18. Renal cancer treatment with low levels of mixed chimerism induced by nonmyeloablative regimen using cyclophosphamide in mice. Harano M; Eto M; Iwai T; Tatsugami K; Kiyoshima K; Kamiryo Y; Tsuneyoshi M; Yoshikai Y; Naito S Cancer Res; 2005 Nov; 65(21):10032-40. PubMed ID: 16267029 [TBL] [Abstract][Full Text] [Related]
19. The graft-versus-leukemia effect of nonmyeloablative stem cell allografts may not be sufficient to cure chronic myelogenous leukemia. Sloand E; Childs RW; Solomon S; Greene A; Young NS; Barrett AJ Bone Marrow Transplant; 2003 Nov; 32(9):897-901. PubMed ID: 14561990 [TBL] [Abstract][Full Text] [Related]